TPST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 105963 min ago

@ $4.10

Wydano: 14 vas. 2024 @ 16:30

Zwrot: -13.66%

Poprzedni sygnał: vas. 13 - 16:30

Poprzedni sygnał: Kupno

Zwrot: -0.93 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	402 127
Średni wolumen	979 955
Kapitalizacja rynkowa	78.65M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $-0.440 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.850
ATR14	$0.0120 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Brady Stephen R	Buy	250 000	Employee Stock Option (right to buy)
2024-01-03	Whiting Samuel	Buy	100 000	Employee Stock Option (right to buy)
2024-01-03	Trojanowski Justin	Buy	26 500	Employee Stock Option (right to buy)
2024-01-03	Maestas Nicholas	Buy	40 000	Employee Stock Option (right to buy)
2023-10-11	Brady Stephen R	Buy	725 000	Employee Stock Option (right to buy)

INSIDER POWER
99.69
Last 85 transactions
Buy: 12 322 880 \| Sell: 50 340

Wolumen Korelacja

Długi: 0.01 (neutral)

Krótki: -0.68 (moderate negative)

Signal:(42.86) Neutral

Tempest Therapeutics, Korelacja

10 Najbardziej pozytywne korelacje
SIFY	0.842
SVOK	0.816
FORE	0.814

10 Najbardziej negatywne korelacje
RAVN	-0.856

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tempest Therapeutics, Korelacja - Waluta/Towar

0.58
( weak )

0.66
( moderate )

0.00
( neutral )

0.66
( moderate )

0.00
( neutral )

-0.05
( neutral )

Tempest Therapeutics, Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2023
Przychody:	$0
Zysk brutto:	$-381 000 (0.00 %)
EPS:	$-1.910

FY	2022
Przychody:	$0
Zysk brutto:	$-1.81M (0.00 %)
EPS:	$-3.18

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-4.27

Financial Reports:

No articles found.

Tempest Therapeutics,

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.